A Simple Study May Herald a Big Change in Evidence-Based Medicine
Sensible Medicine
JUNE 5, 2023
For instance, in the FOURIER trial, the super-expensive PCSCK9 inhibitor, evolocumab, reduced a primary composite outcome (CV death, MI, Stroke, unstable angina, coronary revascularization) vs placebo. We call this acute ischemic stroke or AIS. We are shocked at the response this newsletter has achieved. A brief word of thanks.
Let's personalize your content